CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

VERAXA Biotech (VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration

PartnershipBispecific ADCPositive
AI Analysis

Summary

VERAXA Biotech advances its bispecific antibody-drug conjugate (ADC) program through an ongoing collaboration with OmniAb. The announcement represents progress in the bispecific ADC development pipeline.

Importance:5/10
Sentiment:
0.40
bispecificADCcollaborationantibody
Related Companies

Read the original article

Published by yahoo_finance on July 27, 2026 7:37 PM

Read Original